medac GmbH, the German oncology, haematology and autoimmune specialists, has launched a range of vials of the fibrinolytic agent, urokinase.
Urokinase medac is indicated for intravascular lysis of blood clots in the following conditions:
• Extensive acute proximal deep vein thrombosis
• Acute massive pulmonary embolism
• Acute occlusive peripheral arterial disease with limb threatening ischemia
• Thrombosed haemodialysis
• Thrombosed central venous catheters
It can be administered by systemic intravenous infusion, local intra arterial catheter directed infusion during arteriography or by local instillation.
Urokinase medac will be on national CMU contract for England from 1 April 2012. However, medac is able to offer the contract price now in order that savings can be realised as soon as possible. Contract prices are also available in Scotland, Wales and Northern Ireland.
Urokinase medac is available in a range of vial sizes which include:
10,000IU, 50,000IU, 100,000IU, 250,000IU and 500,000IU.